At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 156 enrolled
Drug / intervention
EVARREST™ Fibrin Sealant Patch +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-blinded, Randomized, Controlled, Comparative Phase III Study Evaluating the Safety and Effectiveness of EVARREST™ Fibrin Sealant Patch as an Adjunct to Hemostasis During Cardiovascular Surgery
In Brief
A Phase 3 clinical trial evaluating EVARREST™ Fibrin Sealant Patch and Topical hemostat for Cardiovascular Disease. Completed, enrolled 156 participants across 24 sites in 5 countries.
Detailed Summary
The objective of this study is to evaluate the safety and effectiveness of the EVARREST™ Fibrin Sealant Patch as an adjunct to hemostasis during cardiovascular surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Disease
CountriesAustralia, Belgium, Japan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
First PostedJan 2014
Primary CompletionJul 2015
Study CompletionSep 2015
TodayJul 2026
First PostedJan 20, 2014
Enrollment StartJan 1, 2014
Primary CompletionJul 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 12.5 years ago
Interventions
EVARREST™ Fibrin Sealant Patchbiological
Topical hemostatbiological